[go: up one dir, main page]

WO2012102242A1 - Timbre transdermique adhésif hydraté - Google Patents

Timbre transdermique adhésif hydraté Download PDF

Info

Publication number
WO2012102242A1
WO2012102242A1 PCT/JP2012/051366 JP2012051366W WO2012102242A1 WO 2012102242 A1 WO2012102242 A1 WO 2012102242A1 JP 2012051366 W JP2012051366 W JP 2012051366W WO 2012102242 A1 WO2012102242 A1 WO 2012102242A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
adhesive layer
nonionic surfactant
water
support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/051366
Other languages
English (en)
Japanese (ja)
Inventor
川村　尚久
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nipro Patch Co Ltd
Original Assignee
Nipro Patch Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Patch Co Ltd filed Critical Nipro Patch Co Ltd
Priority to CN201280006051.4A priority Critical patent/CN103501779B/zh
Priority to JP2012554786A priority patent/JP5781097B2/ja
Priority to KR1020137020064A priority patent/KR20140035879A/ko
Publication of WO2012102242A1 publication Critical patent/WO2012102242A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Definitions

  • the present invention relates to a hydrous patch.
  • patches have been developed in which an adhesive layer containing an active ingredient in an adhesive is positioned on a support for transdermal administration instead of oral administration of drugs and intravenous administration by injection.
  • the patch is useful in that it can percutaneously absorb a substantially constant amount of the active ingredient over a long period of time from when it is applied to the skin until it is peeled off.
  • the adhesive layer of the patch contains various components including an adhesive in addition to the active ingredient, whereby the active ingredient in the patch is likely to deteriorate over time, It is important to improve its stability.
  • the present invention has been made in view of the above circumstances, and an object thereof is to provide a water-containing patch excellent in stability of an active ingredient (drug) having a predetermined cyclic ketone structure such as loxoprofen.
  • the present inventors have found that the reactivity (decomposability) of an active ingredient having a predetermined cyclic ketone structure in an aqueous system is suppressed by a nonionic surfactant, and the present invention has been completed. Specifically, the present invention provides the following.
  • a hydrous patch comprising a support and a pressure-sensitive adhesive layer located on the support,
  • the pressure-sensitive adhesive layer is a hydrous patch containing an active ingredient comprising a compound represented by the general formula 1, a pharmacologically acceptable salt or solvate thereof, a nonionic surfactant, and water.
  • Agent. ....
  • General formula 1 In the formula, n is 0, 1, or 2, and R is an organic group.
  • the nonionic surfactant is selected from the group consisting of polyoxyethylene hydrogenated castor oil (5 moles of added ethylene oxide) and polyoxyethylene lauryl ether (2 moles of added ethylene oxide).
  • the water-containing patch according to (4) which is one or more types.
  • a hydrous patch comprising a support and an adhesive layer located on the support,
  • the pressure-sensitive adhesive layer is blended together with an active ingredient comprising a compound represented by general formula 1, a pharmacologically acceptable salt or solvate thereof, and water, and the compound is represented by general formula 2 or general formula 3.
  • an active ingredient comprising a compound represented by general formula 1, a pharmacologically acceptable salt or solvate thereof, and water, and the compound is represented by general formula 2 or general formula 3.
  • an active ingredient having a predetermined cyclic ketone structure in an aqueous system since the reactivity of an active ingredient having a predetermined cyclic ketone structure in an aqueous system is suppressed by a nonionic surfactant, it has a predetermined cyclic ketone structure such as loxoprofen in a hydrous patch.
  • the stability of the active ingredient can be improved.
  • the patch according to the present invention comprises a support and a pressure-sensitive adhesive layer located on the support, the pressure-sensitive adhesive layer comprising a compound represented by the general formula 1, a pharmacologically acceptable salt thereof, or It contains at least an active ingredient composed of a solvate, a nonionic surfactant, and water.
  • Nonionic surfactants have heretofore been used as surfactants in aqueous patches, but were not expected to be useful as drug stabilizers.
  • the inventor has surprisingly discovered that a nonionic surfactant suppresses the reactivity (degradability) of an active ingredient having a predetermined cyclic ketone structure in an aqueous patch.
  • a nonionic surfactant having an HLB value of 6.0 or more and 9.5 or less and / or an ethylene oxide addition type and an ethylene oxide addition mole number of 5 mol or less is an aqueous patch.
  • the compound represented by the general formula 1 is prevented from changing to the compound represented by the general formula 2 or 3. Note that this reaction is completely different from esterification of an active ingredient (particularly, formation of an ester with menthol or the like) (for details, see Journal of Chromatography A, 2008, 1208, p.164-174).
  • the change from General Formula 1 to General Formula 2 occurs when the bond between the ketone carbon and the ⁇ -position carbon is cleaved, and the change from General Formula 1 to General Formula 3 is the ⁇ -position carbon. Is produced by hydroxylation.
  • n since the carbon number and R of the cyclic structure are considered not to contribute, n may be 0, 1, or 2, and R may be any organic group.
  • the stability of the active ingredient in the present invention means that the sum of the compounds of the general formulas 2 and 3 produced from the compound of the general formula 1 is reduced. Preferably, both the compounds of the general formulas 2 and 3 are produced. Although the amount is reduced, it is sufficient that at least one of the production amounts is reduced.
  • the compound represented by the general formula 1 is not particularly limited, and may be loxoprofen or the like.
  • the pharmacologically acceptable salt is a salt of the above compound and / or a solvate thereof, and is not particularly limited.
  • an alkali metal salt such as a sodium salt or a potassium salt, an alkali such as a calcium salt or a magnesium salt is used. It may be one kind or two or more kinds of earth metal salts.
  • the solvate is a solvate of the above compound and / or a pharmacologically acceptable salt thereof, and is not particularly limited, but is generally a hydrate.
  • the active ingredient (drug) may be formulated in any form such as a salt, a free form, a solvate (for example, hydrate), and a non-solvate (for example, non-hydrate).
  • loxoprofen is generally compounded in the form of a sodium salt / dihydrate represented by the following chemical formula 1, but is not particularly limited, and other salts, free forms, non-hydrated You may mix
  • a nonionic surfactant suppresses the production
  • the nonionic surfactant having an HLB value of 6.0 or more and 9.5 or less is not particularly limited, and glyceryl stearate (containing 20% monoglyceride, HLB value 7.0), polyglyceryl monostearate (HLB value 9) 0.0), polyglyceryl tristearate (HLB value 9.5), decaglyceryl tristearate (HLB value 7.5), polyglyceryl trioleate (HLB value 7.0), polyoxyethylene glyceryl monostearate (oxidized) Ethylene addition mole number 5.
  • HLB value 9.5 palm oil fatty acid sorbitan (HLB value 8.6), sorbitan monopalmitate (HLB value 6.7), monostearate polyoxyethylene sorbitan (ethylene oxide addition mole number) 6.
  • HLB value 9.5 tetraoleic acid polyoxyethylene sorbite (oxidized ethylene) Addition mole number 6.
  • HLB value 8.5 polyoxyethylene hydrogenated castor oil (ethylene oxide addition mole number 5.
  • HLB value 6.0 polyoxyethylene hydrogenated castor oil (ethylene oxide addition mole number 10.
  • HLB value) 6.5 polyoxyethylene phytosterol (ethylene oxide addition mole number 5.
  • HLB value 9.5 polyoxyethylene lauryl ether (ethylene oxide addition mole number 2.
  • HLB value 9.5 polyoxyethylene stearyl ether ( Ethylene oxide addition mole number 2. HLB value 8.0), polyoxyethylene lauryl ether (ethylene oxide addition mole number 4. HLB value 9.0), polyoxyethylene oleyl ether (ethylene oxide addition mole number 2. HLB value 7) .5), polyoxyethylene behenyl ether (ethylene oxide addition mole number 5. HLB value 7. ), Polyoxyethylene polyoxypropylene cetyl ether (ethylene oxide addition mole number 1. propylene oxide addition mole number 4. HLB value 9.5), polyoxyethylene polyoxypropylene cetyl ether (ethylene oxide addition mole number 1.
  • the number of added moles may be one or two or more, such as an HLB value of 9.5) and polyethylene glycol monooleate (ethylene oxide added mole number of 6, HLB value 8.5). Moreover, it is an ethylene oxide addition type
  • the blending amount of the nonionic surfactant is not particularly limited, but is preferably 10 to 500% by mass with respect to the blending amount of the active ingredient.
  • the blending amount of the nonionic surfactant may generally be selected from a range of 3.0% by mass or less with respect to the pressure-sensitive adhesive layer.
  • the blending amount of other components for the purpose of stability may be small or may not be blended.
  • the pressure-sensitive adhesive layer may contain one or more selected from the group consisting of sulfite, hydrogen sulfite, and pyrosulfite, but the compounding amount is based on the compounding amount of the active ingredient, It may be 1% by mass or less.
  • the sulfite may be an alkali metal salt such as sodium salt or potassium salt of hydrogen sulfite, an alkaline earth metal salt such as calcium salt or barium salt, and the bisulfite is an alkali metal such as sodium salt or potassium salt. It may be a salt, an ammonium salt, or the like, and the pyrosulfite may be an alkali metal salt such as a sodium salt or a potassium salt, specifically sodium sulfite, sodium bisulfite, or sodium pyrosulfite.
  • the pressure-sensitive adhesive layer in the water-containing patch according to the present invention contains water.
  • the blending amount of water is not particularly limited, but may be about 30 to 70% by mass with respect to the pressure-sensitive adhesive layer.
  • the pressure-sensitive adhesive layer may be prepared by dissolving excipients such as polyacrylic acid and / or a salt thereof, a surfactant, a cross-linking agent, a cross-linking control agent, an adhesion enhancing agent, a moisturizing agent, and a drug.
  • excipients such as polyacrylic acid and / or a salt thereof, a surfactant, a cross-linking agent, a cross-linking control agent, an adhesion enhancing agent, a moisturizing agent, and a drug.
  • An optional component such as an auxiliary agent, a pH adjuster, a cooling agent, a water-soluble polymer compound, an inorganic powder, an antioxidant, a preservative, and a pigment may be included.
  • polyacrylic acid and / or salts thereof examples include polyacrylic acid, sodium polyacrylate, and partially neutralized polyacrylic acid “NP-800 (trade name)” and “NP-700 (trade name)” (Showa Denko) These may be included alone or in combination of two or more.
  • a general surfactant may be blended.
  • surfactants include anionic surfactants such as sodium dioctylsulfosuccinate, alkyl sulfate salts, sodium 2-ethylhexylalkylsulfate, sodium normal dodecylbenzenesulfonate; hexadecyltrimethylammonium chloride, octadecyldimethylbenzyl.
  • Cationic surfactants such as ammonium chloride and polyoxyethylene dodecyl monomethyl ammonium chloride may be added.
  • Examples of the crosslinking agent include polyvalent metal salts, and among them, aluminum compounds are preferable.
  • Aluminum compounds include hydroxides such as dihydroxyaluminum aminoacetate and aluminum hydroxide, or salts of inorganic or organic acids such as aluminum chloride, aluminum sulfate, aluminum acetate and aluminum stearate, and aluminum alum. Examples thereof include double salts, aluminates such as sodium aluminate, inorganic aluminum complex salts, and organic aluminum chelate compounds. These aluminum compounds may be water-soluble or sparingly soluble.
  • aluminum hydroxide gel may be used as a crosslinking agent.
  • the pH is preferably 4.5 or more and 6.0 or less.
  • the pH of the pressure-sensitive adhesive layer may be more than 6.0.
  • the pH can be set using a pH adjuster, such as tartaric acid, phosphoric acid, malic acid, citric acid, hydrochloric acid, sodium hydroxide, triethanolamine, diethanolamine, diisopropanolamine, etc. These may be included singly or in combination of two or more, but tartaric acid is preferred.
  • a pH adjuster such as tartaric acid, phosphoric acid, malic acid, citric acid, hydrochloric acid, sodium hydroxide, triethanolamine, diethanolamine, diisopropanolamine, etc. These may be included singly or in combination of two or more, but tartaric acid is preferred.
  • adhesion enhancer examples include methacrylic acid / n-butyl acrylate copolymer, methyl acrylate / 2-ethylhexyl acrylate copolymer, polybutene, ester gum, terpene resin, alicyclic saturated hydrocarbon resin, and the like. .
  • the blending amount thereof may be 1% by mass or more and 30% by mass or less, and preferably 2% by mass or more and 10% by mass or less with respect to the pressure-sensitive adhesive layer.
  • humectants include concentrated glycerin, sorbitol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, liquid paraffin, 1,3-propanediol, 1,3-butylene glycol, polyhydric alcohols such as maltitol and xylitol. These may be included singly or in combination of two or more, and among them, concentrated glycerin is preferable. In addition, the blending amount of glycerin may be appropriately set in consideration of the manufacturing cost, the ease of occurrence of bleeding, and the like.
  • Drug dissolution aids include crotamiton, pyrrolidone derivatives such as N-methyl-2-pyrrolidone, mint oil, 1,3-butylene glycol, etc., and these may be used alone or in combination of two or more. It's okay.
  • Examples of the refreshing agent include camphor and thymol, l-menthol, dl-menthol, 2-methyl-3- (l-menthyloxy) propane-1,2-diol, 3-l-mentoxypropane-1, Examples include menthol derivatives such as 2-diol and 5-methyl-2- (1-methylethyl) -cyclohexyl-2-hydroxypropionate, and these may be included singly or in combination of two or more. .
  • water-soluble polymer compounds include gelatin, agar, polyvinyl alcohol, polyvinyl pyrrolidone, propylene carbonate, carboxymethylcellulose, carmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, sodium alginate, maleic anhydride copolymer , Carrageenan and the like, and these may be included singly or in combination of two or more.
  • antioxidants examples include tocopherol acetate, ascorbic acid and / or derivatives thereof, sodium sulfite, dibutylhydroxytoluene and the like, and these may be used alone or in combination of two or more.
  • the type of the dye is not particularly limited, and examples thereof include dyes described in the Legal Dye Handbook, and these can be used alone or in combination of two or more.
  • the support may be composed of a fabric such as a woven fabric, a non-woven fabric, and a knitted fabric used in conventionally known patches, a resin film, paper, and a laminate thereof.
  • the material of the support may be one or more selected from the group consisting of polypropylene, polyethylene, polybutylene, polyethylene terephthalate, rayon, cotton, and polyurethane, and is not particularly limited, but is preferably polyethylene terephthalate. From the viewpoint of cost, a support composed of a nonwoven fabric made of polyethylene terephthalate is preferably used.
  • the patch according to the present invention may further include a release liner that covers the pressure-sensitive adhesive layer.
  • a release liner a resin film such as polyethylene terephthalate or polypropylene is preferable, and a release film such as silicon or an embossed film may be used.
  • what printed or kneaded paints, such as white, can also be used as a peeling liner.
  • Test Example 1 Each component shown in Table 1 was stirred and mixed for a certain period of time, and then uniformly spread on the release liner so that the adhesive mass per patch (140 mm ⁇ 100 mm) was about 10 g. Then, the patch was prepared by bonding together the nonwoven fabric made from a polyethylene terephthalate on the surface of an adhesive layer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un timbre transdermique adhésif hydraté, dans lequel la stabilité d'un principe actif possédant une structure de cétone cyclique donnée (tel que le loxoprofène) est excellente. Ledit timbre transdermique adhésif hydraté comprend un support et une couche adhésive placée sur ledit support, ladite couche adhésive contenant un principe actif qui comprend un composé doté d'une structure de cétone cyclique donnée, son sel pharmacologiquement acceptable ou son solvate, un tensio-actif non-ionique, et de l'eau. Ledit tensio-actif non-ionique possède de préférence une valeur d'équilibre hydrophile-lipophile comprise entre 6,0 et 9,5, et est de préférence un tensio-actif de type adduit d'oxyde d'éthylène. Le nombre de moles d'oxyde d'éthylène ajouté est de préférence égal ou inférieur à 5.
PCT/JP2012/051366 2011-01-24 2012-01-23 Timbre transdermique adhésif hydraté Ceased WO2012102242A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201280006051.4A CN103501779B (zh) 2011-01-24 2012-01-23 含水性贴附剂
JP2012554786A JP5781097B2 (ja) 2011-01-24 2012-01-23 含水系貼付剤
KR1020137020064A KR20140035879A (ko) 2011-01-24 2012-01-23 함수계 첩부제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-012406 2011-01-24
JP2011012406 2011-01-24

Publications (1)

Publication Number Publication Date
WO2012102242A1 true WO2012102242A1 (fr) 2012-08-02

Family

ID=46580809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/051366 Ceased WO2012102242A1 (fr) 2011-01-24 2012-01-23 Timbre transdermique adhésif hydraté

Country Status (5)

Country Link
JP (4) JP5781097B2 (fr)
KR (1) KR20140035879A (fr)
CN (1) CN103501779B (fr)
TW (1) TW201236701A (fr)
WO (1) WO2012102242A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473132A (zh) * 2013-08-23 2016-04-06 久光制药株式会社 泥罨剂及其制造方法
WO2016104227A1 (fr) * 2014-12-22 2016-06-30 久光製薬株式会社 Cataplasme
CN107106513A (zh) * 2015-02-24 2017-08-29 久光制药株式会社 泥罨剂
JP2020158502A (ja) * 2019-03-25 2020-10-01 第一三共ヘルスケア株式会社 ロキソプロフェン配合皮膚外用剤
US11903915B2 (en) 2019-02-14 2024-02-20 Hisamitsu Pharmaceutical Co., Inc. Poultice

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6613878B2 (ja) * 2015-12-25 2019-12-04 ライオン株式会社 口腔用ポリマーゲル製剤
JP6594937B2 (ja) * 2016-09-05 2019-10-23 久光製薬株式会社 シート状パック剤及びその製造方法
KR102000435B1 (ko) * 2018-01-18 2019-07-16 대화제약 주식회사 하이드로겔 패치 형태의 경피투여용 약학 조성물
JP2019206497A (ja) * 2018-05-30 2019-12-05 小林製薬株式会社 外用医薬組成物
KR20210065931A (ko) * 2018-09-26 2021-06-04 니찌방 가부시기가이샤 함수계 첩부제
JP2020164471A (ja) * 2019-03-29 2020-10-08 ニチバン株式会社 貼付材
CN114007594A (zh) * 2019-06-24 2022-02-01 帝国制药株式会社 水性贴剂
JP7649496B2 (ja) * 2020-01-08 2025-03-21 株式会社タフリーインターナショナル 冷感剤組成物
JP7577994B2 (ja) 2020-12-18 2024-11-06 ａｒｔｉｅｎｃｅ株式会社 含水ゲルシート形成用コート剤および含水ゲルシート

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011022A1 (fr) * 1994-10-05 1996-04-18 Hisamitsu Pharmaceutical Co., Inc. Constituants de composition medicamenteuse comprenant des derives de o-toluidine n-substituee et preparation absorbable par voie cutanee
JPH08165251A (ja) * 1994-12-12 1996-06-25 Hisamitsu Pharmaceut Co Inc 溶解剤および該溶解剤を含有する外用製剤
WO2009031318A1 (fr) * 2007-09-05 2009-03-12 Kowa Co., Ltd. Préparation pour une application externe comprenant un agent analgésique/anti-inflammatoire
WO2009075324A1 (fr) * 2007-12-12 2009-06-18 Teikoku Seiyaku Co., Ltd. Plâtre aqueux contenant du loxoprofène

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987171A (ja) * 1995-09-25 1997-03-31 Lion Corp 水性粘着剤組成物の製造法
JPH0987170A (ja) * 1995-09-25 1997-03-31 Lion Corp 水性粘着剤組成物の製造法
JPH10120560A (ja) * 1996-08-26 1998-05-12 Sankyo Co Ltd ロキソプロフェン含有外用製剤
JP2002193793A (ja) * 2000-12-26 2002-07-10 Teikoku Seiyaku Co Ltd 非ステロイド系消炎鎮痛貼付剤
EP2116234A4 (fr) * 2006-12-06 2012-01-18 Nipro Patch Co Ltd Composition pharmaceutique pour application externe et timbre dermique adhesif
KR101490708B1 (ko) * 2008-06-20 2015-02-09 (주)아모레퍼시픽 록소프로펜 또는 그의 염을 포함하는 경피 흡수용 조성물및 이를 포함하는 경피 투여 첩부제
KR20110127678A (ko) * 2009-03-11 2011-11-25 코와 가부시키가이샤 진통·항염증제 함유 외용제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011022A1 (fr) * 1994-10-05 1996-04-18 Hisamitsu Pharmaceutical Co., Inc. Constituants de composition medicamenteuse comprenant des derives de o-toluidine n-substituee et preparation absorbable par voie cutanee
JPH08165251A (ja) * 1994-12-12 1996-06-25 Hisamitsu Pharmaceut Co Inc 溶解剤および該溶解剤を含有する外用製剤
WO2009031318A1 (fr) * 2007-09-05 2009-03-12 Kowa Co., Ltd. Préparation pour une application externe comprenant un agent analgésique/anti-inflammatoire
WO2009075324A1 (fr) * 2007-12-12 2009-06-18 Teikoku Seiyaku Co., Ltd. Plâtre aqueux contenant du loxoprofène

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CHROMATOGR. A., vol. 1208, 2008, pages 164 - 174 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473132B (zh) * 2013-08-23 2019-01-29 久光制药株式会社 泥罨剂及其制造方法
CN105473132A (zh) * 2013-08-23 2016-04-06 久光制药株式会社 泥罨剂及其制造方法
US20160206569A1 (en) * 2013-08-23 2016-07-21 Hisamitsu Pharmaceutical Co., Inc. Cataplasm and Method for Producing the Same
US10369115B2 (en) 2013-08-23 2019-08-06 Hisamitsu Pharmaceutical Co., Ltd. Cataplasm and method for producing the same
TWI672154B (zh) * 2014-12-22 2019-09-21 日商久光製藥股份有限公司 膏劑
US10123977B2 (en) 2014-12-22 2018-11-13 Hisamitsu Pharmaceutical Co., Inc. Gel patch
JPWO2016104227A1 (ja) * 2014-12-22 2017-09-28 久光製薬株式会社 パップ剤
WO2016104227A1 (fr) * 2014-12-22 2016-06-30 久光製薬株式会社 Cataplasme
JPWO2016136556A1 (ja) * 2015-02-24 2017-09-28 久光製薬株式会社 パップ剤
CN107106513A (zh) * 2015-02-24 2017-08-29 久光制药株式会社 泥罨剂
US10940121B2 (en) * 2015-02-24 2021-03-09 Hisamitsu Pharmaceutical Co., Inc. Gel patch
US20210154152A1 (en) * 2015-02-24 2021-05-27 Hisamitsu Pharmaceutical Co., Inc. Gel patch
US11903915B2 (en) 2019-02-14 2024-02-20 Hisamitsu Pharmaceutical Co., Inc. Poultice
JP2020158502A (ja) * 2019-03-25 2020-10-01 第一三共ヘルスケア株式会社 ロキソプロフェン配合皮膚外用剤
JP7515277B2 (ja) 2019-03-25 2024-07-12 第一三共ヘルスケア株式会社 ロキソプロフェン配合皮膚外用剤

Also Published As

Publication number Publication date
JP5981488B2 (ja) 2016-08-31
JPWO2012102242A1 (ja) 2014-06-30
JP2014156499A (ja) 2014-08-28
JP5702489B2 (ja) 2015-04-15
CN103501779B (zh) 2016-08-10
KR20140035879A (ko) 2014-03-24
CN103501779A (zh) 2014-01-08
JP5781097B2 (ja) 2015-09-16
JP2014156497A (ja) 2014-08-28
JP2014156498A (ja) 2014-08-28
TW201236701A (en) 2012-09-16

Similar Documents

Publication Publication Date Title
JP5981488B2 (ja) 含水系貼付剤
JP5001271B2 (ja) 新規テープ製剤
EP2191828B1 (fr) Composition pharmaceutique antifongique
KR102000435B1 (ko) 하이드로겔 패치 형태의 경피투여용 약학 조성물
KR20140054248A (ko) 함수 첩부제
TW201609200A (zh) 含水型貼劑
ES2457519T3 (es) Pasta a base de agua que contiene diclofenaco sódico
TWI572373B (zh) Adhesive agent
US20100215721A1 (en) Poultice and process for producing the poultice
WO2014199455A1 (fr) Préparation de mémantine sous forme de patch à absorption percutanée
JP2013216636A (ja) 含水系貼付剤
TW200946147A (en) Butenafine hydrochloride containing hydrophilic patch
US20150329264A1 (en) Packaging
JP5358551B2 (ja) フェニル酢酸誘導体類及びメントール類を含有する消炎鎮痛剤及び消炎鎮痛作用増強方法
WO2006001251A1 (fr) Composition d'atorvastatine a usage externe
JP6512905B2 (ja) フェンタニル含有貼付剤
WO2014017411A1 (fr) Préparation externe de traitement de la trichophytie unguéale
JP2011088890A (ja) 貼付剤
JP6864968B2 (ja) 貼付剤
RU2776063C2 (ru) Рупатадинсодержащий пластырь
JP6322169B2 (ja) 皮膚外用剤
WO2019088010A1 (fr) Préparation pouvant être administrée par voie transdermique
HK1137344B (en) Tape preparation
JP2014129424A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739562

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2012554786

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137020064

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 12739562

Country of ref document: EP

Kind code of ref document: A1